Dermatology specialist Journey Medical Corporation reveals its Q2 2025 financial results in a live call discussion.
Journey Medical Corporation, a leading pharmaceutical company, has announced that its Emrosi™ oral rosacea treatment has achieved approximately 10% market share among high-volume dermatologists as of mid-2025. The company has set a year-end goal to grow this share further by expanding the base of Emrosi prescribers and increasing prescription volume.
During the Q2 2025 Earnings Conference Call on August 12, 2025, Journey Medical's management expressed confidence that the continued momentum will generate strong revenue growth and improve margins, aiming for an accelerated path to profitability within 2025.
Strong Sales and Prescription Growth
Emrosi generated $2.8 million in sales in Q2 2025, contributing to total company revenue of $15 million. The launch showed strong weekly prescription growth, and payer access coverage expanded rapidly, covering over 100 million commercial lives by June 2025 (an 85% increase since May).
By the end of July, EMROSI prescriptions had reached over 12,800, reflecting an impressive pace of growth. Payor access for EMROSI has increased from 30% of commercial lives in May 2025 to approximately 65% as of the call.
Expansion Plans
The company remains focused on expanding the base of EMROSI prescribers, growing prescription volume, expanding payer access, and converting more of the prescription volume into revenue for the second half of the year.
Claude Maraoui, Journey Medical's President and CEO, stated that the company will wait a few more quarters before giving hard guidance for the year due to the early stage of the EMROSI launch. He believes that the market has been stable for rosacea, and the ramp for EMROSI is moving along nicely, with good growth week-over-week and month-over-month.
Other Highlights
- QBREXZA sales were $6.9 million for the quarter.
- Journey Medical’s common stock was added to the small-cap Russell 2000 and broad market Russell 3000 indexes, broadening public awareness and institutional investor ownership of the company's shares.
- The company participated in the ringing of the closing bell for the Nasdaq Exchange.
- EMROSI gained additional visibility with a segment on The Balancing Act on Lifetime TV and clinical data from its Phase III program evaluating EMROSI for the treatment of moderate to severe papulopustular rosacea in adults were presented at the Society of Dermatology Physician Associates or the SDPA Summer Dermatology Conference in June.
In summary, the current market share in this specialist segment stands at about 10%, and Journey Medical aims to increase that share by year-end 2025 through increased prescriber adoption and payer access expansion. The company's focus on expanding EMROSI's reach and improving its market position bodes well for its future growth and profitability.
[1] Journey Medical Corporation Q2 2025 Earnings Conference Call Transcript, Seeking Alpha, August 12, 2025. [2] Journey Medical Corporation Announces Second Quarter 2025 Financial Results, Business Wire, August 12, 2025. [3] Journey Medical Corporation Announces positive results from its Phase III program evaluating EMROSI for the treatment of moderate to severe papulopustular rosacea in adults, Business Wire, June 15, 2025. [4] Journey Medical Corporation Announces Successful Launch of Emrosi™, Business Wire, April 1, 2025. [5] Journey Medical Corporation Reports First Quarter 2025 Financial Results, Business Wire, May 10, 2025.
In light of Journey Medical's successful launch and accelerating growth of Emrosi™, the company's management plans to invest in expanding the prescription base and improving market share. This investment in business development is anticipated to generate substantial financial returns and contribute to overall corporate profitability.
Journey Medical's strategic effort to boost Emrosi's presence in the market and secure broader payer coverage aligns well with the company's mission to enhance health outcomes for rosacea patients, while also positioning itself as a profitable and financially stable enterprise.
